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The regulation of for acetylcholine receptor (AChR), and other muscle-specific proteins been analyzed in experimental 
autoimmune myasthenia and following denervation. The lcvcls of transcripts for the myogenic factors, MyoDl, and 
MRF4, and MRF4 transcript to 3.1 in muscle 
of rats in controls, respectively. MyoDl The increases in and MRF4 
mRNAs wcrc one order of magnitude higher in in the myasthenic muscle. levels of 
and muscle dystrophin transcripts were to 1.7. and 4.7-fold higher in EAMG and 
denervatcd in controls; in MCK and a-actin levels 
1. INTRODUCTION 
and its animal model, 
are 
neuromuscular disorders characterized by weakness 
and fatigability of the voluntary muscle. basic 
defect in MG and is a reduction of 
is the major auto- 
in this disease [l]. Regulation of AChR and its 
subunit mRNAs during is 
complex; the transcript 
are repressed during muscle 
and denervation results in 
The changes in levels of AChR subunit mRNAs 
usually associated in the transcripts 
of as has 
and after denervation of We 
have previously in EAMG the reduction 
in is associated 
in AChR transcripts for the adult 
of receptor [6,fl. We have an in- 
crease of AChR transcripts following 
by a-bungarotoxin (a-BTX) The increases 
in AChR in EAMG and following a-BTX 
treatment qualitatively smaller 
of skeletal muscle-specific transcriptiol? 
0. Ashcr, Departments of Im- 
munology, The Weizmann 
MRF4/Herculin/Myf-6 [13-15’J, has recently 
been identified. Both myogenin and MyoDl have been 
reported to bind to the enhancers, and activate 
transcription of the AChR Q- [16,17] and y- [17,18] 
subunit genes, as well as the genes coding for muscle 
creatine kinase (MCK) [19,2019 myosin light chain 
(MLC) [21] and troponin I [22]. Consistent with the idea 
that these myogenic factors may regulate AChR gene 
transcription in vivo, is the fact that changes in myo- 
genin and MyoDl levels during innervation and after 
denervation of skeletal muscle precede changes in 
AChR mRNA levels [23]. In addition, electrical stimu- 
lation of adult denervated muscle suppresses the in- 
creases of AChR, myogenin and MyoD 1 mRNA 
hBwQi'Ci, CZipZidty to Sk! EX! actwate 
transcription 
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The fact that AChR transcripts were founld to in- 
crease in EAMG, and the possibility that myogenic fac- 
tors modulate transcription of AChR genes, prompted 
us to analyze myogenic factor mRNA expression in 
EAMG. In addition, we have also anaiyzcd mRN.4 
levels for three muscle-specific genes, MCK, a-actin and 
muscle dystrophin, all of which are developmentally 
regulated. Of these three proteins, MCK was shown to 
be trans-activated by MyoDl and myogenin [19,20]. 
Muscle dystrophin is one of the dystrophin isoforms 
which is distributed along muscle fibers and shows a 
high concentration i the junctional folds [27,28]. In this 
study we report that the increase in AChR mRNAs in 
EAMG, and denervation isaccompanied by an increase 
in myogenin, MRF4, and to a lesser extent, muscle 
dystrophin. In contrast, MCK mRNA and ir-actin 
mRNA levels are not significantly different in myas- 
thenic and denervated muscle. The increases associated 
with denervation are in all cases considerably higher 
than those in EAMG. 
2. MATERIALS AND METHODS 
2. I I Anhal model 
EAMG was induced in ten-week old Lewis rats by monthly injec- 
tions with 40 pg of purified Torpedo CdifOrHiCU AChR in complete 
Freund’s adjuwnt (CFA) as described in [6], When myasthcnic 
symptoms were observed, animals were sacriftced and their hindlimb 
muscles were immediately removed for RNA preparation, Denerva- 
tion was performed as described [S] and the muscles were removed 
from the hindlegs one or two weeks following denervation. 
2.2. Northem blot and hybridization probes 
Total RNA was extracted as previously described [6]. Samples of 
RNA (Joy& each) were electrophoresed on 1% agarose formaldehyde 
gels and transferred to GeneScreen Plus (NEN, Du PGNT) filters [6]. 
Hybridhations were performed using the following specific probes: 
the probe for AChR cr-subunit was an &RI fragment derived from 
the mouse a-subunit recombinant DNA (kindly provided by Dr. S. 
Heinemann); the MyoDl probe (kindly provided by Dr. A.B. Lassar) 
was a mouse cDNA fragment hat was cleaved out of the vector 
pEMCl IS with EcoRI; the myogenin probe (kindly provided by Dr. 
W.E. Wright) was a rat cDNA fragment and was cleaved out of the 
pESVMGN vector with EcoRI; the MRF4 probe was a 123 bp rat 
cDNA which was cleaved out of the Gemini 3 vector by /TcoRI and 
Band-II; the a-skeletal ctin probe was a 600 the 
was an oligonucleotide (STGAAGCCACCATGGCGGT- 
CCTGGAT3’); and the dystrophin probe was a cDNA fragment of 
332 bp which was subcloned into the Gemini 3 vector, Only 223 
nuclcotidcs of the resulting cRNA probe arc protected by dystrophin 
mRNA. Autoradioarams ofthe Northern blots were scanned through 
a Molecular Dynamics 300A Computing Densitometer using the Im- 
agcQuant Software to get volume integration (total O.D, in the area 
of the signal). Averages of the results from 3 different blots were 
calculated. 
2.3, RNase protection ussay 
Tbc P,Nasc protection assays were performed as previous!y de- 
scribed [29]. The hybridization was done at 50°C, and RNase d&es- 
tion at 22°C for 75 min. The digestion products were size-fractionated 
on a 6% polyacrylamidc/urca sequencing gel, and the gels were fluo- 
rographcd at 70°C for 18-48 h. 
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Fig. 1. Northern blot hybridization analysis of AChR a-subunit, myo- 
genin, MyoDl and MRF4 mRNAs in EAMG and following denerva- 
tion: (1) control rat; (2) myasthenic rat; (3) denervatcd rat two weeks 
or one week following dcnervation. Total RNA samples (30 ydlanc) 
were sized-fractionated, blotted and hybridized with AChR a-subunit, 
myogenin, MyoDl and MRM cDNA-specific probes, 
3. RESULTS 
We have previously demonstrated that in both 
EAMG- and in a-BTX-treated rats there is an increase 
in the levels of AChR transcripts, although membrane 
AChR content is reduced [6-81. We were interested to 
find out whether, in addition to the increase in AChR 
mRNAs in EAMG, there is a change in the expression 
of myogenic factors. For comparison, we also measured 
the levels of these transcripts following denervation. 
Northern blots of total RNA isolated from either 
normal, myasthenic or denervated rat muscle were hy- 
bridized with cDNA probes coding for the myogenic 
factors, MyoDl, myogenin and MRF4, or for the 
AChR or-subunit. As shown in Fig. 1, the mRNA levels 
for AChR, myogenin and MRF4 are higher in EAMG 
and in two-week denervated muscles, than in normal 
muscle. MyoDl mRNA levels, however, are approxi- 
mately equal in normal, EAMG and 2-week denervated 
muscle. In muscle denervated for one week the MyoDl 
levels are slightly higher than control. By quantitation 
Table I 
Expression of muscle-specilic genes in EAMG and following denerva- 
tion 
Specific mRNA EAMG Denervation 
(fold increase) (fold increase) 
AChR a-subunit 5.24 ?z 1,31 56,‘) f 12.5 
MCK 0.92 2 0.17 0.81 ?: 0.14 
a-Actin 1.02 f 0,35 0.76 1 0.14 
Dystrophin 1.7 f 0.5 4.7 f 1.4 
MyoDl 1.15 & 0.22 0.96 f 0.14 
MyoDl 1.7 I 0.25” 
Myogenin 3.1 f I.8 38.9 f 3.6 
MRF4 2.6 P 0.7 19.3 1 0.6 
The data was obtained from qunntitation of signals on Northern blots 
using densitometric scanning. The values hove been normalized to 
those obtained from control muscle, and represent the fold change 
found in EAMG and two weeks following dcnervation (unless 
otherwise mentioned) (Mean 2 S.D.). The data analyzed was obtained 
from three independent experiments. 
“One-week denervation. 
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Fig. 2, Northern blot analysis of AChR a-subunit, muscle crcatine 
kinase and a-actin mRNA in (1) control, CFA-injected rat, (2) myas- 
thenic rat and (3) denervated rat. Total muscle RNA (30~gIlane) was 
blotted and hybridized with the different specific DNA probes. 
of blots we observed in muscles from rats with EAMG 
a moderate increase in myogenin and MRF4 mRNA 
levels of 3.1- and 2.6.fold, respectively, while MyoDl 
mRNA levels remained stable (Table I). As previously 
reported [8,23,25,30], in these experiments we also ob- 
served a large increase in the level of myogenin (39-fold) 
and MRF4 (19.3-fold) one week (data not shown) or 
two weeks following denervation (Table I). In this set 
of experiments MyoDl transcripts were slightly ele- 
vated following one-week denervation, while two weeks 
following denervation the MyoDl mRNA returned to 
its control, innervated, levels (Fig. 1, Table I). The in- 
crease of MyoDl mRNA levels is higher shortly after 
denervation and drops with time, as has been shown 
previously in mice ([25], A.B. unpublished results). The 
elevation in myogenin and MRF4 is quantitatively com- 
parable to the increase in AChR a-subunit mRNA in 
myasthenia, as well as upon denervation. The level of 
the a-subunit, myogenin and MRF4 transcripts were 
found to be about one order of magnitude higher in 
denervation than in EAMG. 
The expression of myogenic factors during early 
stages of development [23,31] is consistent with a role 
of these factors in activating the expression of a large 
repertoire of skeletal muscle-specific genes during myo- 
genie differentiation. These include genes coding for 
AChR subunits, MCK, a-actin and muscle dystrophin. 
In light of the fact that transcripts for two of the myo- 
genie factors are increased in EAMG and upon 
denervation, we were interested to investigate if expres- 
sion of other muscle specific genes is affected in EAMG 
and denervated muscle. Total RNA extracted from 
myasthenic and denervated rats was analyzed by 
Northern blot hybridization using oligonucleotide 
probes specific for MCK and cDNA probes specific for 
AChR #-subunit and a-actin (Fig. 2). Quantitation of 
blots showed that the levels of MCK mRNA, as well as 
n-actir?, are not changed in EAMG and are slightly 
decreased following denervation (Table I). To analyze 
expression of the muscle dystrophin transcripts, RNase 
protection assays were performed using a cRNA probe 
derived from the C-terminal domain of the dystrophin 
cDNA that protects a region of 223 nucleotides (Fig. 3). 
This RNase protection analysis revealed a slight in- 
crease (1.7.fold) in EAMG and a larger increase (4.7- 
fold) upon denervation of the muscle dystrophin 
mRNA (Table I). 
4. DISCVSSION 
In order to understand how myogenic factors may 
perform different functions in vivo, it is important to 
analyze their temporal and local expression during de- 
velopment and in different biological paradigms. 
Previous studies have shown that MyoDl and myo- 
genin can regulate transcription of skeletal muscle genes 
which are differentially expressed uring development 
and muscle innervation or after nerve-impulse block- 
ade. The observations that AChR mRNA levels are 
higher in EAMG as compared to normal muscle, and 
that AChR is regulated by members of the myogenic 
factors, prompted us to analyze the expression of the 
myogenic factors in EAMG. In addition, we have corn- 
pared the levels of myogenic factor mRNAs in EAMG 
gnd denervation, sin& partial blockage of neuro- 
223 3 
Fig. 3. RNaac protection assay was performed on 20 or 10 ~8 RNA 
sunpics u inciic&4t, dariwd froia ~yxs:hEk ~MyZS~). de~ervated 
(Den) or control (Con) muscles. The radiolaMed RNA probe used 
in this assay is complementary to nucleotidcs 9433-9656 of the rat 
dystrophin cDNA. A specific fl-agmmt of223 nuclcotides i protected. 
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transmission is observed in EAMG. In this report we 
have shown that MyoDl, myogenin and MRF4 levels 
are altered to different extents in both EAMG and upon 
denervation. Myogenin and MRF4 mRNA levels are 
higher in EAMG than in normal adult muscle, whereas 
MyoDl mRNA levels are approximately the same in 
both conditions. The increases due to denervation, as 
previously shown [23,25,30], are approximately IO-fold 
higher. This quantitative difference between EAMG 
and denervation can be explained by the fact that in 
EAMG, as well as following application of a-BTX 
[8,24] or tetrodotoxin [24], the contact between the 
nerve and muscle is not destroyed, as opposed to 
denervation. Therefore, nerve-derived factors may be 
implicated in the regulation of myogenic factor mRNA 
levels in addition to muscle activity. This has been 
proposed for the regulation of AChR mRNAs, where 
total block by either denervation or botulinurn toxin 
[24] leads to large increases in AChR transcripts. It is 
also possible that residual electrical activity in EAMG 
may be sufficient o prevent high accumulation of myo- 
genie factor mRNAs as well as of AChR mRNAs. 
In contrast to the increase of AChR a-subunit and 
myogenic factor mRNAs associated with EAMG and 
denervation, the levels of MCK transcript remained un- 
changed. An interesting paradox, as was previously dis- 
cussed for MCK and MLC [23], is that although 
MyoDl and myogenin can regulate transcription of 
MCK, MLC and AChR genes, MCK and MLC 
transcript levels do not increase after denervation. A 
possible xplanation for these observations i that myo- 
genin and MyoDl may regulate the expression of 
MCK, MLC and AChR genes during differentiation. 
However, later in development in innervated muscle, 
MCK and MLC are regulated either by other members 
of the MyoD family or by other factors (i.e. MEF 2) 
which have been implicated in the regulation of these 
genes in cultured muscle cells [32]. A slight increase in 
the level of muscle dystrophin was observed in EAMG 
and a larger one following denervation. Since muscle 
dystrophin occurs mainly in the junctional folds [28], it 
might be regulated irectly or indirectly by muscle activ- 
ity as well as by the nerve terminal. We do not know yet 
whether the low increase in dystrophin message in 
EAMG may imply that it is also involved in the patho- 
genesis of myasthenia gravis. Finally, it would be inter- 
esting to know if in MG, as found in EAMG, the levels 
of AChR subunit mRNAs, myogenic factor and pos- 
sibly muscle dystrophin mRNAs are also elevated, and 
if these increases are a consequence of the immune 
response to AChR. 
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